#EHA2024: Frontline and emerging therapies for ALL

To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to frontline and emerging therapies for ALL, here.

CONGRESS | POSTER | #EHA2024 | Maria Chies reports the feasibility of a reduced-intensity induction chemotherapy combined with early and intensive PEG-asparaginase administration (2000 UI/sqm on Day 10 and 24) in elderly Ph- ALL patients. CR rate post induction was 69% (9/13), of… pic.twitter.com/ji12tyEQLX

— ALL Hub (@ALL_Hub_) June 17, 2024

CONGRESS | POSTER | #EHA2024 | Hongsheng Zhou reports on the efficacy of olverembatinib (TKI) + chemotherapy or blinatumomab for ND Ph+ ALL. The 1-year OS and EFS was 96.2% and 71.5%, and 100% and 90.0% for TKI + chemotherapy and TKI + blinatumomab, respectively. Safety was… pic.twitter.com/hmHFVkbWx3

— ALL Hub (@ALL_Hub_) June 17, 2024

CONGRESS | POSTER | #EHA2024 | Elias Jabbour @MDAndersonNews reports follow-up for the phase III Golden Gate Study of blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with ND B-ALL. 13/14 (92.9%) patients had CR with blinatumomab & alternating LIC at… pic.twitter.com/hoW72YKUul

— ALL Hub (@ALL_Hub_) June 17, 2024

CONGRESS #EHA2024 | Jose-Maria Ribera @CarrerasIJC reports that ponatinib is associated with substantially higher rates of MRD-neg at any time across age and BCR::ABL1 variant subgroups vs imatinib in analysis of phase III PHALLCON trial of ponatinib vs imatinib in pts with ND… pic.twitter.com/CCagu7cl2D

— ALL Hub (@ALL_Hub_) June 15, 2024

CONGRESS #EHA2024 | Matthew Greenwood @Sydney_Uni presents findings of the phase II ALLG ALL09 SUBLIME study, evaluating blinatumomab as consolidation in adolescent and young adults with CD19+ Ph− #ALL (N=55). The primary endpoint was met, with significant improvement in Day 79… pic.twitter.com/NwP47k9OMK

— ALL Hub (@ALL_Hub_) June 14, 2024

CONGRESS #EHA2024 | Sujith Samarasinghe @GreatOrmondSt shares initial findings from the phase II ALLTogether1 DS trial evaluating blinatumomab as chemotherapy-replacement for children and young adults with Down Syndrome B-cell ALL (N=33). The primary endpoint was met, with 91%… pic.twitter.com/N5vd3PIQJ7

— ALL Hub (@ALL_Hub_) June 14, 2024

CONGRESS #EHA2024 | Anita Rijneveld @ErasmusMC presents 43-mo follow-up results of phase II HOVON(H)-146 study in comparison with the standard arm of preceding H-100, evaluating the addition of blinatumomab to prephase and consolidation in adults with #ALL (N=71). The primary… pic.twitter.com/6dtZ2CuGOt

— ALL Hub (@ALL_Hub_) June 14, 2024

CONGRESS | POSTER | #EHA2024 | Luke Maese @huntsmancancer shares a post-hoc analysis of adverse events from AALL1931 of erwinia asparaginase in ALL/LBL; concluding that the safety profile is comparable with other ASPs, and AEs remained consistent regardless of administration… pic.twitter.com/5XHcMf9JTF

— ALL Hub (@ALL_Hub_) June 14, 2024

CONGRESS | POSTER | #EHA2024 | Josep Maria Ribera shares the final results of the phase 2 PONALFIL trial of ponatinib, chemotherapy and transplantation for newly diagnosed ph+ ALL; concluding that this regimen showed high efficacy and acceptable safety, similar to previous trials… pic.twitter.com/w2HbytAm8o

— ALL Hub (@ALL_Hub_) June 14, 2024